Comparing 150 IU and 225 IU of recombinant FSH in predicted normal responders undergoing GnRH antagonist stimulatio n in IVF/ICSI: a randomised controlled trial

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100051116

Enrollment

Unknown

Registered

2021-09-14

Start date

2021-10-01

Completion date

Unknown

Last updated

2022-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Interventions

Group 1:Initial dose 150IU

Group 2:Initial dose 225IU

Eligibility

Sex/Gender

Female

Age

20 Years to 38 Years

Inclusion criteria

Inclusion criteria: 1. Aged 1.11ng/ml; 3. BMI=18-25 kg/m^2 4. Those who have received in vitro fertilization embryo transfer or intracytoplasmic sperm injection for the first time; 5. Ovarian stimulation scheme is antagonist scheme; 6. Both husband and wife fully understand and voluntarily participate in the pilot project.

Exclusion criteria

Exclusion criteria: 1. Factors that seriously affect embryo implantation: hydrosalpinx, adenomyosis, intrauterine adhesions, uterine malformations, stage III and IV endometriosis, etc.; 2. Preimplantation genetic test (PGT); 3. Patients with combined medical diseases such as cardiovascular, liver, kidney and hematopoietic system.

Design outcomes

Primary

Measure	Time frame
Number of oocytes;	—

Countries

China

Contacts

Public ContactCai He

Northwest Women's and Children's Hospital of Xi'an Jiaotong University

caihe@bjmu.edu.cn+86 13581613908

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026